Catalyst Brief

← Calendar

Readoutin 45d

Merck Sharp & Dohme LLC — 9vHPV Vaccine

Phase 3 primary completion: Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049).

Date
Jan 2027
Type
Readout
Indication
Papillomavirus Infections

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Merck Sharp & Dohme LLC

  1. Jan2027
  2. Nov2026